Login Register Cart 0
Current Cardiology Reviews

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Phytoconstituents-mediated Targeting of Ferroptosis for the Treatment of Cardiovascular Disease

Author(s): Parul Gupta, Anjali Sharma*orcid of author, Sachin, Shubham Sharma and Devkant Sharma

Volume 22, Issue 1, 2026

Published on: 24 June, 2025

Article ID: e1573403X370981

Pages: 16

DOI: 10.2174/011573403X370981250618074406

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Ferroptosis, an instance of iron-dependent programmable cell death that results from oxidative stress & lipid peroxidation, has garnered interest due to its associations with cardiovascular diseases, such as atherosclerosis, myocardial infarction, as well as heart failure. Unlike necrosis or apoptosis, ferroptosis involves unique metabolic pathways that disrupt cellular redox balance and lipid homeostasis, leading to substantial cell damage in cardiovascular tissues. It is becoming recognized that phytoconstituents—bioactive compounds derived from plants—can modify ferroptosis pathways and provide cardioprotective advantages. Compounds including curcumin, resveratrol, quercetin, tanshinone IIA, and epigallocatechin gallate (EGCG) have shown potential in preclinical studies by concentrating on significant ferroptotic processes. Finally, by controlling iron homeostasis, boosting antioxidant responses (such as Nrf2 pathway activation), and reducing lipid peroxidation, these phytochemicals may mitigate ferroptosisinduced cardiac cell death. In animal studies, these natural compounds have shown promise in reducing oxidative damage and improving heart function after injury. This article summarises the mechanisms via which a variety of phytoconstituents influence ferroptosis and discusses their potential as an adjuvant treatment for CVD. While these findings are encouraging, further research is needed to use them in clinical settings, with a focus on long-term safety in human populations, optimal dose, and absorption. The cardioprotective properties of phytoconstituents, which focus on ferroptosis, may provide a unique, plant-based therapeutic strategy for the treatment of CVDs.

Keywords: Ferroptosis, CVD, phytoconstituents, redox balance, atherosclerosis, resveratrol, quercetin.

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R. Heart disease and stroke statistics-2017 update: A report from the American heart association. Circulation 2017; 135(10): e146-603.
[2]
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J Am Coll Cardiol 2020; 76(25): 2982-3021.
[http://dx.doi.org/10.1016/j.jacc.2020.11.010] [PMID: 33309175]
[3]
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012; 149(5): 1060-72.
[4]
Winterbourn CC. Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicol Lett 1995; 82-83: 969-74.
[5]
Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171(2): 273-85.
[http://dx.doi.org/10.1016/j.cell.2017.09.021] [PMID: 28985560]
[6]
Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 2017; 13(1): 81-90.
[http://dx.doi.org/10.1038/nchembio.2238] [PMID: 27842066]
[7]
Esterbauer H, Zollern H. Methods for determination of aldehydic lipid peroxidation products. Free Radic Biol Med 1989; 7(2): 197-203.
[http://dx.doi.org/10.1016/0891-5849(89)90015-4] [PMID: 2680787]
[8]
Zhang HL, Hu BX, Li ZL, et al. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nat Cell Biol 2022; 24(1): 88-98.
[http://dx.doi.org/10.1038/s41556-021-00818-3] [PMID: 35027735]
[9]
Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 2017; 13(1): 91-8.
[http://dx.doi.org/10.1038/nchembio.2239] [PMID: 27842070]
[10]
Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA 2016; 113(34): E4966-75.
[http://dx.doi.org/10.1073/pnas.1603244113] [PMID: 27506793]
[11]
McBean GJ. The transsulfuration pathway: A source of cysteine for glutathione in astrocytes. Amino Acids 2012; 42(1): 199-205.
[http://dx.doi.org/10.1007/s00726-011-0864-8] [PMID: 21369939]
[12]
Shimada K, Stockwell BR. tRNA synthase suppression activates de novo cysteine synthesis to compensate for cystine and glutathione deprivation during ferroptosis. Mol Cell Oncol 2016; 3(2): e1091059.
[http://dx.doi.org/10.1080/23723556.2015.1091059] [PMID: 27308611]
[13]
Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ 2016; 23(2): 270-8.
[http://dx.doi.org/10.1038/cdd.2015.93] [PMID: 26184909]
[14]
Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 2015; 59(2): 298-308.
[http://dx.doi.org/10.1016/j.molcel.2015.06.011] [PMID: 26166707]
[15]
Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway. Mol Cancer 2017; 16(1): 79.
[http://dx.doi.org/10.1186/s12943-017-0648-1] [PMID: 28407774]
[16]
Sun X, Ou Z, Chen R, et al. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 2016; 63(1): 173-84.
[http://dx.doi.org/10.1002/hep.28251] [PMID: 26403645]
[17]
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 2007; 87(1): 245-313.
[http://dx.doi.org/10.1152/physrev.00044.2005] [PMID: 17237347]
[18]
Magtanong L, Ko PJ, Dixon SJ. Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ 2016; 23(7): 1099-109.
[http://dx.doi.org/10.1038/cdd.2016.25] [PMID: 26967968]
[19]
Fan Z, Wirth A-K, Chen D, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 2017; 6(8): e371.
[http://dx.doi.org/10.1038/oncsis.2017.65] [PMID: 28805788]
[20]
Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014; 16(12): 1180-91.
[http://dx.doi.org/10.1038/ncb3064] [PMID: 25402683]
[21]
Chen H, Attieh ZK, Su T, et al. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 2004; 103(10): 3933-9.
[http://dx.doi.org/10.1182/blood-2003-09-3139] [PMID: 14751926]
[22]
Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews N. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999; 21(4): 396-9.
[http://dx.doi.org/10.1038/7727] [PMID: 10192390]
[23]
Stoyanovsky DA, Tyurina YY, Shrivastava I, et al. Iron catalysis of lipid peroxidation in ferroptosis: Regulated enzymatic or random free radical reaction? Free Radic Biol Med 2019; 133: 153-61.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.09.008] [PMID: 30217775]
[24]
Liochev SI. The mechanism of “Fenton-like” reactions and their importance for biological systems. A biologist’s view. Met Ions Biol Syst 1999; 36: 1-39.
[PMID: 10093922]
[25]
Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15(3): 234-45.
[http://dx.doi.org/10.1016/j.chembiol.2008.02.010] [PMID: 18355723]
[26]
Gao M, Monian P, Jiang X. Metabolism and iron signaling in ferroptotic cell death. Oncotarget 2015; 6(34): 35145-6.
[http://dx.doi.org/10.18632/oncotarget.5671] [PMID: 26387139]
[27]
Hirota K. An intimate crosstalk between iron homeostasis and oxygen metabolism regulated by the hypoxia-inducible factors (HIFs). Free Radic Biol Med 2019; 133: 118-29.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.07.018] [PMID: 30053508]
[28]
Shindou H, Shimizu T. Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem 2009; 284(1): 1-5.
[http://dx.doi.org/10.1074/jbc.R800046200] [PMID: 18718904]
[29]
Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G. Iron-induced damage in cardiomyopathy: Oxidative-dependent and independent mechanisms. Oxid Med Cell Longev 2015; 2015: 1-10.
[http://dx.doi.org/10.1155/2015/230182] [PMID: 25878762]
[30]
Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016; 12(8): 1425-8.
[http://dx.doi.org/10.1080/15548627.2016.1187366] [PMID: 27245739]
[31]
Silva AMN, Rangel M. The (bio)chemistry of non-transferrin-bound iron. Molecules 2022; 27(6): 1784.
[http://dx.doi.org/10.3390/molecules27061784] [PMID: 35335148]
[32]
Porter JB, Walter PB, Neumayr LD, et al. Mechanisms of plasma non‐transferrin bound iron generation: Insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Br J Haematol 2014; 167(5): 692-6.
[http://dx.doi.org/10.1111/bjh.13081] [PMID: 25209728]
[33]
Loréal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC. Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol 2000; 32(5): 727-33.
[http://dx.doi.org/10.1016/S0168-8278(00)80240-8] [PMID: 10845658]
[34]
Aruoma OI, Bomford A, Polson RJ, Halliwell B. Nontransferrin-bound iron in plasma from hemochromatosis patients: Effect of phlebotomy therapy. Blood 1988; 72(4): 1416-9.
[http://dx.doi.org/10.1182/blood.V72.4.1416.1416] [PMID: 2458783]
[35]
Van Campenhout A, Van Campenhout C, Lagrou AR, Moorkens G, De Block C, Manuel-y-Keenoy B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic Biol Med 2006; 40(10): 1749-55.
[http://dx.doi.org/10.1016/j.freeradbiomed.2006.01.010] [PMID: 16678014]
[36]
Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40(2): 255-63.
[http://dx.doi.org/10.1111/j.1365-2141.1978.tb03662.x] [PMID: 708645]
[37]
Jiang LR, Shen MQ, Bao YX, Qian ZM. Verapamil downregulates iron uptake and upregulates divalent metal transporter 1 expression in H9C2 cardiomyocytes. Fundam Clin Pharmacol 2022; 36(6): 985-91.
[http://dx.doi.org/10.1111/fcp.12793] [PMID: 35487763]
[38]
Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, Chattipakorn N. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 2011; 86(2): 156-66.
[http://dx.doi.org/10.1111/j.1600-0609.2010.01549.x] [PMID: 21059103]
[39]
Kumfu S, Chattipakorn S, Fucharoen S, Chattipakorn N. Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels. Drug Chem Toxicol 2013; 36(3): 329-34.
[http://dx.doi.org/10.3109/01480545.2012.726625] [PMID: 23050671]
[40]
Nawi AM, Chin SF, Azhar Shah S, Jamal R. Tissue and serum trace elements concentration among colorectal patients: A systematic review of case-control studies. Iran J Public Health 2019; 48(4): 632-43. [PMID: 31110973
[41]
Liu G, Xie X, Liao W, et al. Ferroptosis in cardiovascular disease. Biomed Pharmacother 2024; 170: 116057.
[http://dx.doi.org/10.1016/j.biopha.2023.116057] [PMID: 38159373]
[42]
Wang Y, Kuang X, Yin Y, et al. Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction. Biomed Pharmacother 2022; 145: 112367.
[http://dx.doi.org/10.1016/j.biopha.2021.112367] [PMID: 34740097]
[43]
Wang X, Zhang M, Mao C, et al. Icariin alleviates ferroptosis‐related atherosclerosis by promoting autophagy in xo‐LDL‐induced vascular endothelial cell injury and atherosclerotic mice. Phytother Res 2023; 37(9): 3951-63.
[http://dx.doi.org/10.1002/ptr.7854] [PMID: 37344941]
[44]
Rong J, Li C, Zhang Q, et al. Hydroxysafflor yellow A inhibits endothelial cell ferroptosis in diabetic atherosclerosis mice by regulating miR-429/SLC7A11. Pharm Biol 2023; 61(1): 404-15.
[http://dx.doi.org/10.1080/13880209.2023.2225543] [PMID: 37410531]
[45]
Mylonas KS, Peroulis M, Schizas D, Kapelouzou A. MYD88 and proinflammatory chemokines in aortic atheromatosis: Exploring novel statin effects. Int J Mol Sci 2023; 24(11): 9248.
[http://dx.doi.org/10.3390/ijms24119248] [PMID: 37298199]
[46]
Li Q, Liu C, Deng L, et al. Novel function of fluvastatin in attenuating oxidized low density lipoprotein induced endothelial cell ferroptosis in a glutathione peroxidase4 and cystine glutamate antiporter dependent manner. Exp Ther Med 2021; 22(5): 1275.
[http://dx.doi.org/10.3892/etm.2021.10710]
[47]
Fang X, Wang H, Han D, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA 2019; 116(7): 2672-80.
[http://dx.doi.org/10.1073/pnas.1821022116] [PMID: 30692261]
[48]
Park TJ, Park JH, Lee GS, et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis 2019; 10(11): 835.
[http://dx.doi.org/10.1038/s41419-019-2061-8] [PMID: 31685805]
[49]
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12(12): 931-47.
[http://dx.doi.org/10.1038/nrd4002] [PMID: 24287781]
[50]
Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol 2019; 23: 101107.
[http://dx.doi.org/10.1016/j.redox.2019.101107] [PMID: 30692038]
[51]
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 2017; 547(7664): 453-7.
[http://dx.doi.org/10.1038/nature23007] [PMID: 28678785]
[52]
Bulluck H, Rosmini S, Abdel-Gadir A, et al. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling. Circ Cardiovasc Imaging 2016; 9(10): e004940.
[http://dx.doi.org/10.1161/CIRCIMAGING.116.004940] [PMID: 27894068]
[53]
Chen X, Xu S, Zhao C, Liu B. Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure. Biochem Biophys Res Commun 2019; 516(1): 37-43.
[http://dx.doi.org/10.1016/j.bbrc.2019.06.015] [PMID: 31196626]
[54]
Liu B, Zhao C, Li H, Chen X, Ding Y, Xu S. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem Biophys Res Commun 2018; 497(1): 233-40.
[http://dx.doi.org/10.1016/j.bbrc.2018.02.061] [PMID: 29427658]
[55]
Zhou N, Wei S, Sun T, et al. Recent progress in the role of endogenous metal ions in doxorubicin-induced cardiotoxicity. Front Pharmacol 2023; 14: 1292088.
[http://dx.doi.org/10.3389/fphar.2023.1292088] [PMID: 38143497]
[56]
Oyama J, Shiraki A, Nishikido T, et al. EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice. J Cardiol 2017; 69(2): 417-27.
[http://dx.doi.org/10.1016/j.jjcc.2016.05.019] [PMID: 27374189]
[57]
Zhu K, Fan R, Cao Y, et al. Glycyrrhizin attenuates myocardial ischemia reperfusion injury by suppressing Inflammation, oxidative stress, and ferroptosis via the HMGB1-TLR4-GPX4 pathway. Exp Cell Res 2024; 435(1): 113912.
[http://dx.doi.org/10.1016/j.yexcr.2024.113912] [PMID: 38176464]
[58]
Fan Z, Cai L, Wang S, Wang J, Chen B. Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting ACSL4 mediated ferroptosis. Front Pharmacol 2021; 12: 628988.
[http://dx.doi.org/10.3389/fphar.2021.628988] [PMID: 33935719]
[59]
Yang KT, Chao TH, Wang IC, et al. Berberine protects cardiac cells against ferroptosis. Tzu-Chi Med J 2022; 34(3): 310-7.
[http://dx.doi.org/10.4103/tcmj.tcmj_236_21] [PMID: 35912047]
[60]
Hu T, Zou HX, Le SY, et al. Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1. Int J Mol Med 2023; 52(5): 109.
[http://dx.doi.org/10.3892/ijmm.2023.5312] [PMID: 37800609]
[61]
Chen J, Huang Q, Li J, et al. Panax ginseng against myocardial ischemia/reperfusion injury: A review of preclinical evidence and potential mechanisms. J Ethnopharmacol 2023; 300: 115715.
[http://dx.doi.org/10.1016/j.jep.2022.115715] [PMID: 36108895]
[62]
Ye W, Wang J, Little PJ, et al. Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba. Acta Pharm Sin B 2024; 14(1): 1-19.
[http://dx.doi.org/10.1016/j.apsb.2023.09.014] [PMID: 38239238]
[63]
Wang B, Wang J, Liu C, Li C, Meng T, Chen J. Ferroptosis: Latest evidence and perspectives on plant‐derived natural active compounds mitigating doxorubicin‐induced cardiotoxicity. J Appl Toxicol 2024.
[PMID: 39030835]
[64]
Li T, Tan Y, Ouyang S, He J, Liu L. Resveratrol protects against myocardial ischemia-reperfusion injury via attenuating ferroptosis. Gene 2022; 808: 145968.
[http://dx.doi.org/10.1016/j.gene.2021.145968] [PMID: 34530090]
[65]
Wang K, Dong Y, Liu J, et al. Effects of REDOX in regulating and treatment of metabolic and inflammatory cardiovascular diseases. Oxid Med Cell Longev 2020; 2020(1): 1-13.
[http://dx.doi.org/10.1155/2020/5860356] [PMID: 33282111]
[66]
Huang P, Wan H, Shao C, Li C, Zhang L, He Y. Recent advances in Chinese herbal medicine for cerebral ischemic reperfusion injury. Front Pharmacol 2022; 12: 688596.
[http://dx.doi.org/10.3389/fphar.2021.688596] [PMID: 35111041]
[67]
Jiang M, Ni J, Cao Y, Xing X, Wu Q, Fan G. Astragaloside IV attenuates myocardial ischemia‐reperfusion injury from oxidative stress by regulating succinate, lysophospholipid metabolism, and ROS scavenging system. Oxid Med Cell Longev 2019; 2019(1): 1-17.
[http://dx.doi.org/10.1155/2019/9137654] [PMID: 31341538]
[68]
Hu S, Zhou J, Hao J, et al. Emodin ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis through the remodeling of gut microbiota composition. Am J Physiol Cell Physiol 2024; 326(1): C161-76.
[http://dx.doi.org/10.1152/ajpcell.00477.2023] [PMID: 38009195]
[69]
Bellavite P, Fazio S, Affuso F. A descriptive review of the action mechanisms of berberine, quercetin and silymarin on insulin resistance/hyperinsulinemia and cardiovascular prevention. Molecules 2023; 28(11): 4491.
[http://dx.doi.org/10.3390/molecules28114491] [PMID: 37298967]
[70]
Lu L, Xiong Y, Zhou J, Wang G, Mi B, Liu G. The therapeutic roles of cinnamaldehyde against cardiovascular diseases. Oxid Med Cell Longev 2022; 2022(1): 1-23.
[http://dx.doi.org/10.1155/2022/9177108] [PMID: 36254234]
[71]
Zhang T, Deng W, Deng Y, et al. Mechanisms of ferroptosis regulating oxidative stress and energy metabolism in myocardial ischemia-reperfusion injury and a novel perspective of natural plant active ingredients for its treatment. Biomed Pharmacother 2023; 165: 114706.
[http://dx.doi.org/10.1016/j.biopha.2023.114706] [PMID: 37400352]
[72]
Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients 2016; 8(5): 250.
[http://dx.doi.org/10.3390/nu8050250] [PMID: 27144581]
[73]
Malaguarnera L. Influence of resveratrol on the immune response. Nutrients 2019; 11(5): 946.
[http://dx.doi.org/10.3390/nu11050946] [PMID: 31035454]
[74]
Hu LF, Lan HR, Li XM, Jin KT. A systematic review of the potential chemoprotective effects of resveratrol on doxorubicin-induced cardiotoxicity: Focus on the antioxidant, antiapoptotic, and anti-inflammatory activities. Oxid Med Cell Longev 2021; 2021: 2951697.
[http://dx.doi.org/10.1155/2021/295169]
[75]
Yu W, Chen C, Xu C, et al. Activation of p62-NRF2 axis protects against doxorubicininduced ferroptosis in cardiomyocytes: A novel role and molecular mechanism of resveratrol. Am J Chin Med 2022; 50(8): 2103-23.
[http://dx.doi.org/10.1142/S0192415X22500902] [PMID: 36309811]
[76]
Chen L, Sun X, Wang Z, et al. Resveratrol protects against doxorubicin-induced cardiotoxicity by attenuating ferroptosis through modulating the MAPK signaling pathway. Toxicol Appl Pharmacol 2024; 482: 116794.
[http://dx.doi.org/10.1016/j.taap.2023.116794] [PMID: 38142782]
[77]
Li Y, Meeran SM, Tollefsbol TO. Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression. Sci Rep 2017; 7(1): 9345.
[http://dx.doi.org/10.1038/s41598-017-09764-3] [PMID: 28839265]
[78]
Wang L, Li P, Feng K. EGCG adjuvant chemotherapy: Current status and future perspectives. Eur J Med Chem 2023; 250: 115197.
[http://dx.doi.org/10.1016/j.ejmech.2023.115197]
[79]
Li W, Nie S, Xie M, Chen Y, Li C, Zhang H. A major green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. J Agric Food Chem 2010; 58(16): 8977-82.
[http://dx.doi.org/10.1021/jf101277t] [PMID: 20666448]
[80]
Zheng J, Lee HC, Bin Sattar MM, Huang Y, Bian JS. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur J Pharmacol 2011; 652: 82-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.10.082]
[81]
Saeed NM, El-Naga RN, El-Bakly WM, Abdel-Rahman HM, Salah ElDin RA, El-Demerdash E. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. Biochem Pharmacol 2015; 95(3): 145-55.
[http://dx.doi.org/10.1016/j.bcp.2015.02.006] [PMID: 25701654]
[82]
Yao YF, Liu X, Li WJ, et al. (−)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice. Life Sci 2017; 180: 151-9.
[http://dx.doi.org/10.1016/j.lfs.2016.12.004] [PMID: 27956351]
[83]
He H, Wang L, Qiao Y, Yang B, Yin D, He M. Epigallocatechin-3-gallate pretreatment alleviates doxorubicin-induced ferroptosis and cardiotoxicity by upregulating AMPKα2 and activating adaptive autophagy. Redox Biol 2021; 48: 102185.
[http://dx.doi.org/10.1016/j.redox.2021.102185] [PMID: 34775319]
[84]
Kwiecień I, Miceli N, D’Arrigo M, Marino A, Ekiert H. Antioxidant potential and enhancement of bioactive metabolite production in in vitro cultures of Scutellaria lateriflora L. by biotechnological methods. Molecules 2022; 27(3): 1140.
[http://dx.doi.org/10.3390/molecules27031140] [PMID: 35164404]
[85]
Hu Q, Zhang W, Wu Z, et al. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. Pharmacol Res 2021; 165: 105444.
[http://dx.doi.org/10.1016/j.phrs.2021.105444] [PMID: 33493657]
[86]
El-Ela SRA, Zaghloul RA, Eissa LA. Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways. Nutrition 2022; 102: 111732.
[http://dx.doi.org/10.1016/j.nut.2022.111732] [PMID: 35816809]
[87]
Feng P, Yang Y, Liu N, Wang S. Baicalin regulates TLR4/IκBα/NFκB signaling pathway to alleviate inflammation in Doxorubicin related cardiotoxicity. Biochem Biophys Res Commun 2022; 637: 1-8.
[http://dx.doi.org/10.1016/j.bbrc.2022.10.061]
[88]
Zeng Y, Liao X, Guo Y, et al. Baicalin-peptide supramolecular self-assembled nanofibers effectively inhibit ferroptosis and attenuate doxorubicin-induced cardiotoxicity. J Control Release 2024; 366: 838-48.
[http://dx.doi.org/10.1016/j.jconrel.2023.12.034] [PMID: 38145663]
[89]
Wongnen C, Ruzzama N, Chaijan M, Cheong LZ, Panpipat W. Glochidion wallichianum leaf extract as a natural antioxidant in sausage model system. Foods 2022; 11(11): 1547.
[http://dx.doi.org/10.3390/foods11111547] [PMID: 35681297]
[90]
Zhu R, Liu H, Liu C, et al. Cinnamaldehyde in diabetes: A review of pharmacology, pharmacokinetics and safety. Pharmacol Res 2017; 122: 78-89.
[http://dx.doi.org/10.1016/j.phrs.2017.05.019] [PMID: 28559210]
[91]
Li L, Zhang W, Peng J, et al. A novel shell material-highland barley starch for microencapsulation of cinnamon essential oiwith different preparation methods. Materials 2020; 13(5): 1192.
[http://dx.doi.org/10.3390/ma13051192] [PMID: 32155895]
[92]
Nile A, Shin J, Shin J, et al. Cinnamaldehyde-rich cinnamon extract induces cell death in colon cancer cell lines HCT 116 and HT-29. Int J Mol Sci 2023; 24(9): 8191.
[http://dx.doi.org/10.3390/ijms24098191] [PMID: 37175897]
[93]
Zhao M, Zheng Z, Pan W, et al. TRPA1 deficiency aggravates dilated cardiomyopathy by promoting S100A8 expression to induce M1 macrophage polarization in rats. FASEB J 2023; 37(6): e22982.
[http://dx.doi.org/10.1096/fj.202202079RR] [PMID: 37219522]
[94]
Mao M, Zheng W, Deng B, et al. Cinnamaldehyde alleviates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and ferroptosis in cardiomyocytes. PLoS One 2023; 18(10): e0292124.
[http://dx.doi.org/10.1371/journal.pone.0292124] [PMID: 37824478]
[95]
Musolino M, D’Agostino M, Zicarelli M, Andreucci M, Coppolino G, Bolignano D. Spice up your kidney: A review on the effects of capsaicin in renal physiology and disease. Int J Mol Sci 2024; 25(2): 791.
[http://dx.doi.org/10.3390/ijms25020791] [PMID: 38255865]
[96]
López M, Quintero-Macías L, Huerta M, et al. Capsaicin decreases kidney iron deposits and increases hepcidin levels in diabetic rats with iron overload: A preliminary study. Molecules 2022; 27(22): 7764.
[http://dx.doi.org/10.3390/molecules27227764] [PMID: 36431865]
[97]
Wang L, Liu Y, Li S, et al. Capsaicin alleviates doxorubicin-induced acute myocardial injury by regulating iron homeostasis and PI3K-Akt signaling pathway. Aging 2023; 15(21): 11845-59.
[http://dx.doi.org/10.18632/aging.205138] [PMID: 37916995]
[98]
Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis 2019; 10(2): 142.
[http://dx.doi.org/10.1038/s41419-019-1366-y] [PMID: 30760707]
[99]
Kumar RM, Kumar H, Bhatt T, et al. Fisetin in cancer: attributes, developmental aspects, and nanotherapeutics. Pharmaceuticals 2023; 16(2): 196.
[http://dx.doi.org/10.3390/ph16020196] [PMID: 37259344]
[100]
Ma T, Kandhare AD, Mukherjee-Kandhare AA, Bodhankar SL. Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: The decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-α. Mol Biol Rep 2019; 46(1): 105-18.
[http://dx.doi.org/10.1007/s11033-018-4450-y] [PMID: 30362071]
[101]
Lin KH, Ramesh S, Agarwal S, et al. Fisetin attenuates doxorubicin‐induced cardiotoxicity by inhibiting the insulin‐like growth factor II receptor apoptotic pathway through estrogen receptor‐α/‐β activation. Phytother Res 2023; 37(9): 3964-81.
[http://dx.doi.org/10.1002/ptr.7855] [PMID: 37186468]
[102]
Li D, Liu X, Pi W, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation. Front Pharmacol 2022; 12: 808480.
[http://dx.doi.org/10.3389/fphar.2021.808480] [PMID: 35273493]
[103]
Chen X, Liu Z, Meng R, Shi C, Guo N. Antioxidative and anticancer properties of Licochalcone A from licorice. J Ethnopharmacol 2017; 198: 331-7.
[http://dx.doi.org/10.1016/j.jep.2017.01.028] [PMID: 28111219]
[104]
Li MT, Xie L, Jiang HM, et al. Role of licochalcone A in potential pharmacological therapy: A review. Front Pharmacol 2022; 13: 878776.
[http://dx.doi.org/10.3389/fphar.2022.878776] [PMID: 35677438]
[105]
de Freitas KS, Squarisi IS, Acésio NO, et al. Licochalcone A, a licorice flavonoid: Antioxidant, cytotoxic, genotoxic, and chemopreventive potential. J Toxicol Environ Health A 2020; 83(21-22): 673-86.
[http://dx.doi.org/10.1080/15287394.2020.1813228] [PMID: 32886024]
[106]
Chen G, Luo S, Guo H, Lin J, Xu S. Licochalcone A alleviates ferroptosis in doxorubicin-induced cardiotoxicity via the PI3K/AKT/MDM2/p53 pathway. Naunyn Schmiedebergs Arch Pharmacol 2023; 397(6): 4247-62.
[http://dx.doi.org/10.1007/s00210-023-02863-1] [PMID: 38078919]
[107]
Thuan NH, Shrestha A, Trung NT, et al. Advances in biochemistry and the biotechnological production of taxifolin and its derivatives. Biotechnol Appl Biochem 2022; 69(2): 848-61.
[http://dx.doi.org/10.1002/bab.2156] [PMID: 33797804]
[108]
Liu Y, Shi X, Tian Y, et al. An insight into novel therapeutic potentials of taxifolin. Front Pharmacol 2023; 14: 1173855.
[http://dx.doi.org/10.3389/fphar.2023.1173855] [PMID: 37261284]
[109]
Alzaharna M, Alqouqa I, Cheung HY. Taxifolin synergizes Andrographolide-induced cell death by attenuation of autophagy and augmentation of caspase dependent and independent cell death in HeLa cells. PLoS One 2017; 12(2): e0171325.
[http://dx.doi.org/10.1371/journal.pone.0171325] [PMID: 28182713]
[110]
Unver E, Tosun M, Olmez H, Kuzucu M, Cimen FK, Suleyman Z. The effect of taxifolin on cisplatin-induced pulmonary damage in rats: A biochemical and histopathological evaluation. Mediators Inflamm 2019; 2019: 1-6.
[http://dx.doi.org/10.1155/2019/3740867] [PMID: 30992689]
[111]
Lin Z, Wang J. Taxifolin protects against doxorubicin-induced cardiotoxicity and ferroptosis by adjusting microRNA-200a-mediated Nrf2 signaling pathway. Heliyon 2023; 9(11): e22011.
[http://dx.doi.org/10.1016/j.heliyon.2023.e22011] [PMID: 38053888]
[112]
Liu Y, Tang BL, Lu ML, Wang HX. Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway. J Cell Mol Med 2023; 27(5): 622-33.
[http://dx.doi.org/10.1111/jcmm.17681] [PMID: 36762748]
[113]
Zhang Y, Zhang Y, Jin X, et al. The role of Astragaloside IV against cerebral ischemia/reperfusion injury: Suppression of apoptosis via promotion of P62-LC3-autophagy. Molecules 2019; 24(9): 1838.
[http://dx.doi.org/10.3390/molecules24091838] [PMID: 31086091]
[114]
Jia Y, Zuo D, Li Z, et al. Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull 2014; 62(1): 45-53.
[http://dx.doi.org/10.1248/cpb.c13-00556] [PMID: 24390491]
[115]
Lin J, Fang L, Li H, et al. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. Eur J Pharmacol 2019; 859: 172490.
[http://dx.doi.org/10.1016/j.ejphar.2019.172490] [PMID: 31229536]
[116]
Chen X, Tian C, Zhang Z, et al. Astragaloside IV inhibits NLRP3 inflammasome-mediated pyroptosis via activation of Nrf-2/HO-1 signaling pathway and protects against doxorubicin-induced cardiac dysfunction. Front Biosci 2023; 28(3): 45.
[http://dx.doi.org/10.31083/j.fbl2803045] [PMID: 37005753]
[117]
Luo LF, Guan P, Qin LY, Wang JX, Wang N. Ji ES. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling. Mol Cell Biochem 2021; 476(7): 2603-11.
[http://dx.doi.org/10.1007/s11010-021-04112-6] [PMID: 33656642]
[118]
Gackowski M, Szewczyk-Golec K, Mądra-Gackowska K, Pluskota R, Koba M. Quantitative structure-activity relationship analysis of isosteviol-related compounds as activated coagulation factor X (FXa) inhibitors. Nutrients 2022; 14(17): 3521.
[http://dx.doi.org/10.3390/nu14173521] [PMID: 36079779]
[119]
Wang M, Li H, Xu F, et al. Diterpenoid lead stevioside and its hydrolysis products steviol and isosteviol: Biological activity and structural modification. Eur J Med Chem 2018; 156: 885-906.
[http://dx.doi.org/10.1016/j.ejmech.2018.07.052] [PMID: 30059803]
[120]
Xu C, Ou E, Li Z, et al. Synthesis and in vivo evaluation of new steviol derivatives that protect against cardiomyopathy by inhibiting ferroptosis. Bioorg Chem 2022; 129: 106142.
[http://dx.doi.org/10.1016/j.bioorg.2022.106142] [PMID: 36150232]
[121]
Dong X, Fu J, Yin X, et al. Emodin: A review of its pharmacology, toxicity and pharmacokinetics. Phytother Res 2016; 30(8): 1207-18.
[http://dx.doi.org/10.1002/ptr.5631] [PMID: 27188216]
[122]
HaoShang, Jia X, Liu H, Zhang X, Shao Y. A comprehensive review of emodin in fibrosis treatment. Fitoterapia 2023; 165: 105358.
[http://dx.doi.org/10.1016/j.fitote.2022.105358] [PMID: 36436587]
[123]
Dai S, Chen Y, Fan X, et al. Emodin attenuates cardiomyocyte pyroptosis in doxorubicin-induced cardiotoxicity by directly binding to GSDMD. Phytomedicine 2023; 121: 155105.
[http://dx.doi.org/10.1016/j.phymed.2023.155105] [PMID: 37801893]
[124]
Xian M, Cai J, Zheng K, et al. Aloe-emodin prevents nerve injury and neuroinflammation caused by ischemic stroke via the PI3K/AKT/mTOR and NF-κB pathway. Food Funct 2021; 12(17): 8056-67.
[http://dx.doi.org/10.1039/D1FO01144H] [PMID: 34286782]
[125]
Dong X, Zeng Y, Liu Y, et al. Aloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics. Phytother Res 2020; 34(2): 270-81.
[http://dx.doi.org/10.1002/ptr.6532] [PMID: 31680350]
[126]
Wu M, Ling W, Wei J, et al. Biomimetic photosensitizer nanocrystals trigger enhanced ferroptosis for improving cancer treatment. J Control Release 2022; 352: 1116-33.
[http://dx.doi.org/10.1016/j.jconrel.2022.11.026] [PMID: 36402233]
[127]
He Y, Xi J, Fang J, Zhang B, Cai W. Aloe-emodin alleviates doxorubicin-induced cardiotoxicity via inhibition of ferroptosis. Free Radic Biol Med 2023; 206: 13-21.
[http://dx.doi.org/10.1016/j.freeradbiomed.2023.06.025] [PMID: 37364691]
[128]
Li J, Yu H, Yang C, Ma T, Dai Y. Therapeutic potential and molecular mechanisms of echinacoside in neurodegenerative diseases. Front Pharmacol 2022; 13: 841110.
[http://dx.doi.org/10.3389/fphar.2022.841110] [PMID: 35185590]
[129]
Wang W, Jiang S, Zhao Y, Zhu G. Echinacoside: A promising active natural products and pharmacological agents. Pharmacol Res 2023; 197: 106951.
[http://dx.doi.org/10.1016/j.phrs.2023.106951] [PMID: 37804927]
[130]
Ma Y, Yang X, Jiang N, Lu C, Zhang J, Zhuang S. Echinacoside ameliorates doxorubicin induced cardiac injury by regulating GPX4 inhibition induced ferroptosis. Exp Ther Med 2023; 27(1): 29.
[http://dx.doi.org/10.3892/etm.2023.12317] [PMID: 38125366]
[131]
Li L, Zhang W, Peng J, et al. A novel shell material-highland barley starch for microencapsulation of cinnamon essential oil with different preparation methods. Materials 2020; 13(5): 1192.
[http://dx.doi.org/10.3390/ma13051192] [PMID: 32155895]
[132]
Morcillo-Parra MÁ, Beltran G, Mas A, Torija MJ. Determination of melatonin by a whole cell bioassay in fermented beverages. Sci Rep 2019; 9(1): 9120.
[http://dx.doi.org/10.1038/s41598-019-45645-7] [PMID: 31235891]
[133]
Talib WH. Melatonin and cancer hallmarks. Molecules 2018; 23(3): 518.
[http://dx.doi.org/10.3390/molecules23030518] [PMID: 29495398]
[134]
Sun X, Sun P, Zhen D, et al. Melatonin alleviates doxorubicin-induced mitochondrial oxidative damage and ferroptosis in cardiomyocytes by regulating YAP expression. Toxicol Appl Pharmacol 2022; 437: 115902.
[http://dx.doi.org/10.1016/j.taap.2022.115902] [PMID: 35093381]
[135]
Hanna M, Seddiek H, Aboulhoda BE, et al. Synergistic cardioprotective effects of melatonin and deferoxamine through the improvement of ferritinophagy in doxorubicin-induced acute cardiotoxicity. Front Physiol 2022; 13: 1050598.
[http://dx.doi.org/10.3389/fphys.2022.1050598] [PMID: 36531171]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 21
Html icon 3
Find your institution